Ramucirumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ramucirumab: From VEGFR2-Targeted Oncology Therapy to Uterine Ligament Adenocarcinoma
One-Sentence Summary
Ramucirumab is a VEGFR2-targeting monoclonal antibody used in oncology; the evidence pack does not contain data on its originally licensed indication or EU authorization status (marked as not marketed). The TxGNN model predicts it may be effective for Uterine Ligament Adenocarcinoma, a very rare tumour subtype, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure AI knowledge-graph inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in evidence pack (data gap) |
| Predicted New Indication | Uterine Ligament Adenocarcinoma |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available as a structured field in this evidence pack. Based on the rationale text accompanying the prediction, Ramucirumab is a VEGFR2 monoclonal antibody that blocks tumour angiogenesis, a mechanism theoretically relevant to highly vascularised solid tumours.
The predicted indication — uterine ligament adenocarcinoma — is an extremely rare, anatomically specific tumour subtype. While some related cancer types (e.g., cervical and endometrioid adenocarcinomas) are known to show VEGF pathway activation, and anti-angiogenic agents have precedent in gynaecologic oncology (e.g., bevacizumab in metastatic cervical cancer), no data specific to this rare subtype or to Ramucirumab in gynaecologic malignancies is provided. The mechanistic link is plausible in principle but remains entirely theoretical for this specific pairing.
Because the model’s TxGNN score (99.95%) is based purely on knowledge-graph relationships without any supporting clinical or literature evidence, this prediction should be treated as a hypothesis-generating signal only, not as a validated repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
No EU marketing authorizations are recorded for this drug in the evidence pack (0 licenses; market status: not marketed).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (anti-VEGFR2 monoclonal antibody / anti-angiogenic agent) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by AI inference (L5, no clinical trials or literature) for an extremely rare tumour subtype, and critical safety data (warnings, contraindications) are flagged as a Blocking data gap. The drug also shows no current EU marketing authorization in this evidence pack, further limiting near-term actionability.
To proceed, the following is needed:
- SmPC-derived safety data: key warnings and contraindications (currently Blocking data gap DG001)
- Confirmed mechanism of action from DrugBank or regulatory sources (High-priority data gap DG002)
- Verification of Ramucirumab’s original approved indication(s) and current EU regulatory status
- Any preclinical or case-level evidence specifically addressing VEGFR2 blockade in rare gynaecologic adenocarcinoma subtypes before advancing beyond S0
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.